Kiniksa Pharmaceuticals International, plc

Good day and thank you for standing by and welcome to the Kinexa Pharmaceuticals First Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 1-1 on your telephone. You will then hear an automated message advising your hand is raised. To answer a question, please press star 1-1 again. And please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Rachel Frank, Head, Investor Relations. Please go ahead.

Thank you, Operator. Good morning, everyone, and thank you for joining Connexus Call to discuss our first quarter 2023 financial results and recent portfolio execution. A press release highlighting these results can be found on our website under the Investors and Media section. As for the agenda, our Chief Executive Officer, Sanj K. Patel, will start with an introduction. Ross Moat, our Chief Commercial Officer, will provide an update on our ARCLPS commercial execution. Then Mark Vergosa, our Chief Financial Officer, will review our first quarter 2023 financial results. And finally, Sanj will return for closing remarks and to kick off the Q&A session for which Evan Tesari, our Chief Operating Officer, and John Paolini, our Chief Medical Officer, will also be on the line. Before getting started, please note that we will be making forward-looking statements today that are subject to risks and uncertainties that may cause actual results to differ materially from these statements. A review of such statements and risk factors can be found on this slide, as well as under the caption, Risk Factors, contained in our SEC filings. These statements is only at the date of this presentation, and we undertake no obligation to update such statements except as required by law. With that, I will turn it over to Sanj.

Thanks, Rachel, and good morning, everyone. I'm happy to review our first quarter 2023 financial results today. We have continued to execute across our cardiovascular and autoimmune franchises, which positions us for success and growth in 2023. On the commercial side, Q1 represented another quarter of growth for Arculus with a net product revenue $42.7 million. We are encouraged by our commercial execution to date and with recent increased prescriber adoption and patient enrollments, we're seeing clear signs of success from our field team expansion. We've also continued to see high patient satisfaction, strong payer approval rates, as well as longer duration of therapy. With that in mind, we have raised our 2023 expected ARCLIS guidance range to $200 to $215 million. We also remain focused on building the maximum value across our portfolio of clinical stage assets, and that includes KPL-404, which is our CD40 antagonist program. We're currently enrolling the third and final cohort of our Phase II study in rheumatoid arthritis, which is designed to evaluate efficacy, dose response, PK, and safety of chronic sub-Q dosing over a duration of 12 weeks. And we expect data from this study in the first half of next year. Additionally, we continue to pursue collaborative study agreements with Mavilimumab to evaluate its potential in rare cardiovascular diseases. This is a molecule that we continue to be excited about, and it has the potential to impact a number of diseases. So with that, I'll turn it over to Ross to review our commercial execution for ARCLIS. Ross?